[1] BRINK M, HANSSON M, MATHSSON-ALM L, et al. Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis. Arthritis Res Ther. 2016;18:43.
[2] KAPOOR S. Comment on The role of citrullinated protein antibodies in predicting erosive disease in rheumatoid arthritis: a systematic literature review and meta-analysis. Int J Rheumatol. 2015;2015: 175251.
[3] ALETAHA D, NEOGI T, SILMAN AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581.
[4] BUGATTI S, BOGLIOLO L, VITOLO B, et al. Anti-citrullinated protein antibodies and high levels of rheumatoid factor are associated with systemic bone loss in patients with early untreated rheumatoid arthritis. Arthritis Res Ther. 2016;18:226.
[5] KLARESKOG L, CATRINA AI, PAGET S. Rheumatoid arthritis. Lancet. 2009;373:659-672.
[6] DAHA NA, TOES RE. Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease? Nat Rev Rheumatol. 2011;7:202-203.
[7] FERT-BOBER J, DARRAH E, ANDRADE F. Insights into the study and origin of the citrullinome in rheumatoid arthritis. Immunol Rev. 2020; 294:133-147.
[8] DAI X, DAI X, GONG Z, et al. Disease-specific autoantibodies induce trained immunity in RA synovial tissues and its gene signature correlates with the response to clinical therapy. Mediat Inflamm. 2020; 2020:2109325.
[9] DONG X, ZHENG Z, ZHAI Y, et al. ACPA mediates the interplay between innate and adaptive immunity in rheumatoid arthritis. Autoimmun Rev. 2018;17:845-853.
[10] GE C, XU B, LIANG B, et al. Structural Basis of Cross-Reactivity of Anti-Citrullinated Protein Antibodies. Arthritis Rheumatol. 2019;71:210-221.
[11] LU MC, LAI NS, YU HC, et al. Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor alpha production. Arthritis Rheum. 2010;62:1213-1223.
[12] LU MC, LAI NS, YIN WY, et al. Anti-citrullinated protein antibodies activated ERK1/2 and JNK mitogen-activated protein kinases via binding to surface-expressed citrullinated GRP78 on mononuclear cells. J Clin Immunol. 2013;33:558-566.
[13] KUHN KA, KULIK L, TOMOOKA B, et al. Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. J Clin Invest. 2006;116:961-973.
[14] UYSAL H, BOCKERMANN R, NANDAKUMAR KS, et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J Exp Med. 2009;206:449-462.
[15] KIM Y, LEE J, JUNG H, et al. Development of synthetic anti-cyclic citrullinated peptide antibody and its arthritogenic role. J Clin Invest. 2015;4:e51.
[16] KRISHNAMURTHY A, JOSHUA V, HAJ HENSVOLD A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016;75:721-729.
[17] GUSTAF W, DUYGU BB, CÁTIA FC, et al. Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism Correction. Ann Rheum Dis. 2019; 78:865.
[18] GE C, TONG D, LIANG B, et al. Anti-citrullinated protein antibodies cause arthritis by cross-reactivity to joint cartilage. JCI Insight. 2017; 2(13):e93688.
[19] OZAWA T, OUHARA K, TSUDA R, et al. Physiological target, molecular evolution and pathogenic functions of a monoclonal ACPA obtained from an RA patient. Arthritis Rheumatol. 2020;72(12):2040-2049.
[20] SCHELLEKENS GA, VISSER H, DE JONG BA, et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum. 2000;43:155-163.
[21] KLARESKOG L, RöNNELID J, LUNDBERG K, et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol. 2008;26:651-675.
[22] PRATESI F, PANZA F, PAOLINI I, et al. Fingerprinting of anti-citrullinated protein antibodies (ACPA): specificity, isotypes and subclasses. Lupus. 2015;24:433-441.
[23] FOULQUIER C, SEBBAG M, CLAVEL C, et al. Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation. Arthritis Rheum. 2007;56:3541-3553.
[24] 陈恩生,崔明珠,赵晓峰,等.合成环瓜氨酸化蛋白短肽的免疫原性和致关节炎性研究[J]. 中国免疫学杂志,2017,33(1):25-30.
[25] 蔡理,余焙佳,毕亚男,等.合成环瓜氨酸蛋白短肽诱导猕猴类风湿关节炎模型的研究[J].中国免疫学杂志,2019,35(16):1937-1943.
[26] LUNDBERG K, NIJENHUIS S, VOSSENAAR ER, et al. Citrullinated proteins have increased immunogenicity and arthritogenicity and their presence in arthritic joints correlates with disease severity. Arthritis Res Ther. 2005;7:R458-R467.
[27] HILL JA, BELL DA, BRINTNELL W, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med. 2008;205:967-979.
[28] FEITSMA AL, VAN DER VOORT EI, FRANKEN KL, et al. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum. 2010;62:117-125.
[29] KINLOCH A J, ALZABIN S, BRINTNELL W, et al. Immunization with Porphyromonas gingivalis enolase induces autoimmunity to mammalian α-enolase and arthritis in DR4-IE-transgenic mice. Arthritis Rheum. 2011;63:3818-3823.
[30] SHODA H, FUJIO K, SHIBUYA M, et al. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther . 2011;13:R191.
[31] THIELE GM, DURYEE MJ, DUSAD A, et al. Citrullinated mouse collagen administered to DBA/1J mice in the absence of adjuvant initiates arthritis. Int Immunopharmacol. 2012;13:424-431.
[32] DUSAD A, DURYEE MJ, SHAW AT, et al. Induction of bone loss in DBA/1J mice immunized with citrullinated autologous mouse type II collagen in the absence of adjuvant. Immunol Res. 2014;58:51-60.
[33] BEDNAR KJ, NYCHOLAT CM, RAO TS, et al. Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis. ACS Chem Biol. 2019;14:644-654.
[34] THIELE GM, DURYEE MJ, HUNTER CD, et al. Immunogenic and inflammatory responses to citrullinated proteins are enhanced following modification with malondialdehyde-acetaldehyde adducts. Int Immunopharmacol. 2020;83:106433.
[35] KADOWAKI T, NAKAYAMA K, OKAMOTO K, et al. Porphyromonas gingivalis proteinases as virulence determinants in progression of periodontal diseases. J Biochem. 2000;128:153-159.
[36] YAMAKAWA M, OUHARA K, KAJIYA M, et al. Porphyromonas gingivalis infection exacerbates the onset of rheumatoid arthritis in SKG mice. Clin Exp Immunol. 2016;186:177-189.
[37] MIKULS TR, PAYNE JB, YU F, et al. Periodontitis and Porphyromonas gingivalis in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014;66:1090-1100.
[38] MARESZ KJ, HELLVARD A, SROKA A, et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathog. 2013;9:e1003627.
[39] JENNING M, MARKLEIN B, YTTERBERG J, et al. Porphyromonas gingivalisBacterial citrullinated epitopes generated by infection-a missing link for ACPA production. Ann Rheum Dis. 2020;79:1194-1202.
[40] MAROTTE H. Tooth-brushing: an impact on rheumatoid arthritis. Joint Bone Spine. 2016;83:619-621.
[41] GULLY N, BRIGHT R, MARINO V, et al. Porphyromonas gingivalis peptidylarginine deiminase, a key contributor in the pathogenesis of experimental periodontal disease and experimental arthritis. PLoS One. 2014;9:e100838.
[42] DARRAH E. ANDRADE F. Rheumatoid arthritis and citrullination. Curr Opin Rheumatol. 2018;30:72-78.
[43] SAKAI Y, SHIMAUCHI H, ITO H, et al. Porphyromonas gingivalis-specific IgG subclass antibody levels as immunological risk indicators of periodontal bone loss. J Clin Periodontol. 2001;28:853-859.
[44] MARESZ KJ, HELLVARD A, SROKA A, et al. Porphyromonas gingivalis facilitates the development and progression of destructive arthritis through its unique bacterial peptidylarginine deiminase (PAD). PLoS Pathogens. 2013;9:e1003627.
[45] SANDAL I, KARYDIS A, LUO J, et al. Bone loss and aggravated autoimmune arthritis in HLA-DRβ1-bearing humanized mice following oral challenge with Porphyromonas gingivalis. Arthritis Res Ther. 2016; 18:249.
[46] ERIKSSON K, LöNNBLOM E, TOUR G, et al. Effects by periodontitis on pristane-induced arthritis in rats. J Transl Med. 2016;14:311.
[47] MUNENAGA S, OUHARA K, HAMAMOTO Y, et al. The involvement of C5a in the progression of experimental arthritis with Porphyromonas gingivalis infection in SKG mice. Arthritis Res Ther. 2018;20:247.
[48] SAKAGUCHI W, TO M, YAMAMOTO Y, et al. Detection of anti-citrullinated protein antibody (ACPA) in saliva for rheumatoid arthritis using DBA mice infected with Porphyromonas gingivalis. Arch Oral Biol. 2019;108:104510.
[49] COURBON G, RINAUDO-GAUJOUS M, BLASCO-BAQUE V, et al. Porphyromonas gingivalis experimentally induces periodontis and an anti-CCP2-associated arthritis in the rat. Ann Rheum Dis. 2019;78:594-599.
[50] HAMAMOTO Y, OUHARA K, MUNENAGA S, et al. Effect of Porphyromonas gingivalis infection on gut dysbiosis and resultant arthritis exacerbation in mouse model. Arthritis Res Ther. 2020;22:249.
[51] VAN VW, PRUIJN GJ. Citrullination: a small change for a protein with great consequences for rheumatoid arthritis. Arthritis Res. 2000;2:249-251.
[52] ARNOUX F, MARIOT C, PEEN E, et al. Peptidyl arginine deiminase immunization induces anticitrullinated protein antibodies in mice with particular MHC types. PNAS. 2017;114:E10169-E10177.
[53] PRATESI F, TOMMASI C, ANZILOTTI C, et al. Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54:733-741.
[54] CROIA C, SERAFINI B, BOMBARDIERI M, et al. Epstein-Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis. Ann Rheum Dis. 2013;72: 1559-1568.
[55] SCHIFF M, WEINBLATT ME, VALENTE R, et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis. 2014;73:86-94.
[56] HARROLD LR, LITMAN HJ, CONNOLLY SE, et al. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study. J Rheumatol. 2018;45(1):32-39.
[57] COURVOISIER DS, CHATZIDIONYSIOU K, MONGIN D, et al. The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology (Oxford). 2021;60:820-828.
[58] GENOVESE M C, FLEISCHMANN R, KIVITZ A, et al. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies. Arthritis Res Ther. 2020;22:139.
[59] Lü S, WANG Q, LI G, et al. The treatment of rheumatoid arthritis using Chinese medicinal plants: from pharmacology to potential molecular mechanisms. J. Ethnopharmacol. 2015;176:177-206.
[60] MAINI RN, ELLIOTT MJ, BRENNAN FM, et al. Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev. 1995;144:195-223.
[61] SAKAGUCHI N, TAKAHASHI T, HATA H, et al. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 2003;426:454-460.
|